Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years

Rakesh Popat, Zoe Craig, Faith E Davies, David Cairns, Catherine Olivier, J Anthony Child, Gareth J. Morgan, Gordon Cook, Graham H Jackson

Blood (2021) 138 (Supplement 1): 4118.

https://doi.org/10.1182/blood-2021-149148

Published: 2021

Journal Articles

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Charlotte A. Bradbury, Zoe Craig, Gordon Cook, Charlotte Pawlyn, David A. Cairns, Anna Hockaday, Andrea Paterson, Matthew W. Jenner, John R. Jones, Mark T. Drayson, Roger G. Owen, Martin F. Kaiser, Walter M. Gregory, Faith E. Davies, J. Anthony Child, Gareth J. Morgan, Graham H. Jackson

Blood (2020) 136 (9): 1091–1104.

https://doi.org/10.1182/blood.2020005125

Published: 2020

Includes: Supplemental data

Journal Articles

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Gordon Cook, MD PhD, Kara-Louise Royle, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Anna Hockaday, Walter M Gregory, PhD, J Anthony Child, Faith E Davies, MD, Gareth J. Morgan, MD PhD, David Cairns, BSc, MSc, PhD, Graham Jackson, MDPhD

Blood (2017) 130 (Supplement 1): 3063.

https://doi.org/10.1182/blood.V130.Suppl_1.3063.3063

Published: 2017

Journal Articles

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Andy C. Rawstron, Walter M. Gregory, Ruth M. de Tute, Faith E. Davies, Sue E. Bell, Mark T. Drayson, Gordon Cook, Graham H. Jackson, Gareth J. Morgan, J. Anthony Child, Roger G. Owen

Blood (2015) 125 (12): 1932–1935.

https://doi.org/10.1182/blood-2014-07-590166

Published: 2015

Includes: Supplemental data

Journal Articles

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

Annamaria Brioli, Hannah Giles, Charlotte Pawlyn, John P. Campbell, Martin F. Kaiser, Lorenzo Melchor, Graham H. Jackson, Walter M. Gregory, Roger G. Owen, J. Anthony Child, Faith E. Davies, Michele Cavo, Mark T. Drayson, Gareth J. Morgan

Blood (2014) 123 (22): 3414–3419.

https://doi.org/10.1182/blood-2013-12-542662

Published: 2014

Journal Articles

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Charlotte Pawlyn, MD, Lorenzo Melchor, PhD, Eileen M Boyle, MD, Annamaria Brioli, MD, Martin F Kaiser, MD, Walter Gregory, PhD, Mark T Drayson, MD PhD, Graham Jackson, MD, Fiona M Ross, DPhil, J. Anthony Child, MD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2013) 122 (21): 529.

https://doi.org/10.1182/blood.V122.21.529.529

Published: 2013

Journal Articles

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Annamaria Brioli, MD, John P. Campbell, PhD, Martin F Kaiser, MD, Charlotte Pawlyn, MD, Graham H. Jackson, MD, Walter Gregory, PhD, Roger G. Owen, MD, J. Anthony Child, MD, Faith E. Davies, MD, Michele Cavo, MD, Mark T. Drayson, MD PhD, Gareth J. Morgan, MD PhD

Blood (2013) 122 (21): 752.

https://doi.org/10.1182/blood.V122.21.752.752

Published: 2013

Journal Articles

The impact of response on bone-directed therapy in patients with multiple myeloma

Alessandra Larocca, J. Anthony Child, Gordon Cook, Graham H. Jackson, Nigel Russell, Alexander Szubert, Walter M. Gregory, Annamaria Brioli, Roger G. Owen, Mark T. Drayson, Ping Wu, Antonio Palumbo, Mario Boccadoro, Faith E. Davies, Gareth J. Morgan

Blood (2013) 122 (17): 2974–2977.

https://doi.org/10.1182/blood-2013-04-498139

Published: 2013

Journal Articles

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Alex J. Szubert, Sue E. Bell, Mark T. Drayson, Roger G. Owen, A. John Ashcroft, Graham H. Jackson, J. Anthony Child

Blood (2012) 119 (23): 5374–5383.

https://doi.org/10.1182/blood-2011-11-392522

Published: 2012

Includes: Supplemental data

Journal Articles

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Gareth J. Morgan, Walter M. Gregory, Faith E. Davies, Sue E. Bell, Alexander J. Szubert, Julia M. Brown, Nuria N. Coy, Gordon Cook, Nigel H. Russell, Claudius Rudin, Huw Roddie, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group

Blood (2012) 119 (1): 7–15.

https://doi.org/10.1182/blood-2011-06-357038

Published: 2012

Includes: Supplemental data

Journal Articles

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

Gareth J Morgan, MD PhD, Faith E Davies, MD, Walter M Gregory, PhD, Sue E Bell, DPhil, Alex J Szubert, MSc, Gordon Cook, Mark T Drayson, MD, Roger G Owen, MD, Fiona M Ross, DPhil, Graham H Jackson, MD, J. Anthony Child, MD

Blood (2011) 118 (21): 993.

https://doi.org/10.1182/blood.V118.21.993.993

Published: 2011

Journal Articles

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Kevin D Boyd, MD, Fiona M Ross, DPhil, Mark T Drayson, MD, Roger G Owen, MD, Alex J Szubert, MSc, Walter M Gregory, PhD, Christopher P Wardell, PhD, Faith E Davies, MD, Graham H Jackson, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD PhD

Blood (2011) 118 (21): 1823.

https://doi.org/10.1182/blood.V118.21.1823.1823

Published: 2011

Journal Articles

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Nigel H. Russell, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Jenny L. Byrne, Huw Roddie, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, for the NCRI Haematological Oncology Study Group

Blood (2011) 118 (5): 1231–1238.

https://doi.org/10.1182/blood-2011-02-338665

Published: 2011

Includes: Supplemental data

Journal Articles

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Fiona M. Ross, DPhil, Laura Chiecchio, PhD, GianPaolo Dagrada, BSc, William J Tapper, PhD, Zoe J Konn, BSc, Kan Luk Cheung, BSc, Rebecca KM Protheroe, BSc, David M Stockley, BSc, Susan E Bell, DPhil, Walter M Gregory, PhD, Alexander J Szubert, MSc, Gordon Cook, MD, Roger G. Owen, MD, Mark T. Drayson, MD, Graham Jackson, DM, Faith Davies, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 2980.

https://doi.org/10.1182/blood.V116.21.2980.2980

Published: 2010

Journal Articles

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M Gregory, Sue E. Bell, DPhil, Alexander J Szubert, MSc, Mark T. Drayson, MD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, Dr, Graham H. Jackson, MD, Nigel H. Russell, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 311.

https://doi.org/10.1182/blood.V116.21.311.311

Published: 2010

Journal Articles

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M. Gregory, PhD, Sue E. Bell, PhD, Alex J. Szubert, MSc, Nuria Navarro-Coy, MPhil, Mark T. Drayson, MD, PhD, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, PhD, Graham H. Jackson, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 623.

https://doi.org/10.1182/blood.V116.21.623.623

Published: 2010

Journal Articles

Abnormal Serum IgA Kappa / IgA Lambda Ratios at Maximum Response Predict Poor Progression Free Survival in Myeloma Patients.

Heinz Ludwig, MD, Stephen Harding, PhD, Caroline Bradley, Dejan Milosavljevich, Mark T Drayson, Gareth J Morgan, J. Anthony Child, Arthur Bradwell, FRCP, FRCPath

Blood (2009) 114 (22): 4879.

https://doi.org/10.1182/blood.V114.22.4879.4879

Published: 2009

Journal Articles

Serum Free Light Chain and Serum Heavy / Light Chain Ratios Are Independently Prognostic in Multiple Myeloma Patients.

Efstathios Koulieris, Stephen Harding, PhD, Marie-Christine Kyrtsonis, Caroline Bradley, Mark T Drayson, Gareth J Morgan, J. Anthony Child, Arthur Bradwell, FRCP, FRCPath

Blood (2009) 114 (22): 4880.

https://doi.org/10.1182/blood.V114.22.4880.4880

Published: 2009

Journal Articles

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Gareth J Morgan, MD, PhD, Faith E Davies, MD, Walter M Gregory, Susan E Bell, Alex J Szubert, Kim Cocks, Nuria Navarro Coy, Mark T Drayson, Roger G Owen, Fiona M Ross, DPhil, Graham H Jackson, J. Anthony Child

Blood (2009) 114 (22): 352.

https://doi.org/10.1182/blood.V114.22.352.352

Published: 2009

Journal Articles

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

David C. Johnson, Sophie Corthals, Christine Ramos, Antje Hoering, Kim Cocks, Nicholas J. Dickens, Jeff Haessler, Harmut Goldschmidt, J. Anthony Child, Sue E. Bell, Graham Jackson, Dalsu Baris, S. Vincent Rajkumar, Faith E. Davies, Brian G. M. Durie, John Crowley, Pieter Sonneveld, Brian Van Ness, Gareth J. Morgan

Blood (2008) 112 (13): 4924–4934.

https://doi.org/10.1182/blood-2008-02-140434

Published: 2008

Includes: Supplemental data

NARROW

Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

The impact of response on bone-directed therapy in patients with multiple myeloma

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Abnormal Serum IgA Kappa / IgA Lambda Ratios at Maximum Response Predict Poor Progression Free Survival in Myeloma Patients.

Serum Free Light Chain and Serum Heavy / Light Chain Ratios Are Independently Prognostic in Multiple Myeloma Patients.

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only